PPARG and polycystic ovary syndrome: demonstrated in lean women with PCOS that rosiglitazone, a peroxisome proliferator-activated receptor-γ (PPARγ) agonist that stimulates mitochondrial biogenesis (41), increases circulating total antioxidant capacity, decreases circulating malondialdehyde, and decreases insulin resistance (59).